David T Teachey
Children's Oncology Group · Children's Hospital of Philadelphia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David T Teachey as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:04 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02112916 · Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaNational Cancer Institute (NCI) · active not recruiting · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma · principal investigator
- Ph1/Ph2NCT00392951 · Sirolimus for Autoimmune Disease of Blood CellsChildren's Hospital of Philadelphia · completed · Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Characterization and targeting of HSPC-like blasts in high-risk leukemiasR01CA303081 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $744,511 awarded in 2026Same name and institution; not confirmed by an ID
- Improving risk allocation and developing novel therapies for children with T-ALL and T-LLR01CA193776 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2015 to 2026 · $737,350 awarded in 2026Same name and institution; not confirmed by an ID
- The impact of genetic ancestry on Notch1 activation and signaling in T-ALLR01CA315128 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $735,963 awarded in 2026Same name and institution; not confirmed by an ID
- Transcriptomic molecular risk classification for children with B cell acute lymphoblastic leukemiaUH2CA312695 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $350,860 awarded in 2026Same name and institution; not confirmed by an ID
- Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemiaR01CA264837 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · fiscal years 2021 to 2025 · $599,172 awarded in 2025Same name and institution; not confirmed by an ID
- Genomic Profiling of T-cell Acute Lymphoblastic Leukemia in ChildrenR03CA256550 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2021 · $381,969 awarded in 2021Same name and institution; not confirmed by an ID
- Targeting Akt signaling in Autoimmune Lymphoproliferative SyndromeR21AI099301 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2012 to 2013 · $197,833 awarded in 2013Same name and institution; not confirmed by an ID
- Targeting the mTOR signaling pathway in Autoimmune Lymphoproliferative SyndromeR56AI091791 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2011 · $432,341 awarded in 2011Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Children's Oncology Group Chair's GrantU10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013Named on NCT02112916
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT02112916
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 12:04 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med · 20144,475 citationsRCR 122.8
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.Crit Care Med · 2017383 citationsRCR 11.6
- 207 citationsRCR 51.1
- Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.J Clin Oncol · 2022145 citationsRCR 10.2
- 99 citationsRCR 3.0
- MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.Blood · 201598 citationsRCR 2.6
- A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).Clin Cancer Res · 201992 citationsRCR 3.3
- Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.J Clin Oncol · 202064 citationsRCR 2.9
- 56 citationsRCR 7.4
- 55 citationsRCR 4.6